NCT05878899 (PP-HEP) is a Phase 3 clinical trial of Enoxaparin in Venous Thromboembolism, sponsored by University Hospital, Geneva.

Who is sponsoring NCT05878899?

NCT05878899 is sponsored by University Hospital, Geneva.

What drugs are being tested in NCT05878899?

Interventions in NCT05878899: Enoxaparin.

What condition does NCT05878899 study?

NCT05878899 studies Venous Thromboembolism.

Is NCT05878899 still recruiting?

NCT05878899 is currently completed. Last updated 26 May 2023.

Last reviewed 2023-05-26 · How we verify

NCT05878899: PP-HEP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Postpartum Heparin Against Venous Thromboembolism: a Pilot Randomized Controlled Trial

Completed Phase 3 Last updated 26 May 2023

What this trial tests

Phase 3 trial testing Enoxaparin in Venous Thromboembolism in 77 participants. Completed in 13 March 2023.

Timeline

3 May 2022

Primary endpoint
13 March 2023

13 March 2023

Quick facts

Lead sponsor	University Hospital, Geneva
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	77
Start date	3 May 2022
Primary completion	13 March 2023
Estimated completion	13 March 2023
Sites	1 location across Switzerland

Drugs / interventions tested

Enoxaparin — full drug profile →

Conditions studied

Venous Thromboembolism — all drugs for Venous Thromboembolism →

Sponsor

University Hospital, Geneva

Who can join

18 and older, female only, with Venous Thromboembolism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In previous attemps to answer the question of risk-benefit of postpartum thromboprophylaxis, researchers were faced with low recruitement rates. The goal of this pilot feasibility randomized controlled trial of postpartum pharmacological thromboprophylaxis is to examine the feasibility (recruitement rate) and participation rate at the Geneva University Hospitals

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Prevention, diagnosis, and management of PE and DVT in pregnant women.
Kevane B, Áinle FN. · · 2023 · cited 7× · PMID 38066865 · DOI 10.1182/hematology.2023000476
Preventing Postpartum Venous Thromboembolism With Low-Molecular-Weight Heparin: The PP-HEP Pilot Randomised Controlled Trial.
Blondon M, Claver M, Celetta E, Righini M, et al · · 2025 · cited 4× · PMID 39238110 · DOI 10.1111/1471-0528.17943
Postoperative venous thromboembolism following cesarean delivery: prevalence, pathophysiology, diagnosis, treatment, and prevention.
Federspiel JJ, Rodger MA, Hoffman MR, Skeith L, et al · · 2026 · cited 1× · PMID 41485833 · DOI 10.1016/j.ajog.2025.07.055

Verify or expand the search:

Other trials of Enoxaparin

Trials testing the same drug.

NCT07462182 — Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction · NA · not yet recruiting
NCT07312851 — A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Parti · Phase 1 · recruiting
NCT07015905 — REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults · Phase 3 · recruiting
NCT06818279 — Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis · Phase 2, PHASE3 · not yet recruiting
NCT06689241 — Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery · NA · recruiting

Other recruiting trials for Venous Thromboembolism

Currently open trials in the same condition.

NCT07399977 — Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism · NA · recruiting
NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
NCT07140523 — A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA · Phase 2 · recruiting
NCT04211181 — CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism · NA · recruiting
NCT06440694 — Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial) · Phase 3 · recruiting

Other University Hospital, Geneva trials

Trials by the same sponsor.

NCT07506356 — Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors · recruiting
NCT07267624 — EARLY Antibiotics aDAptation in Severe Pneumonia(The EARLY ADAPT Study) · NA · not yet recruiting
NCT06710210 — Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventi · NA · not yet recruiting
NCT07173348 — Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea · NA · not yet recruiting
NCT07129655 — Cholangitis Definition and Treatment After Kasai Hepatoportoenterostomy for Biliary Atresia: TRACK-BA Study (TRacking Ch · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05878899 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Geneva
Last refreshed: 26 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05878899.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing